Today, we are extremely excited to announce a new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases, including Duchenne.
CureDuchenne understands the difficult financial and health-related decisions these times present for many organizations. We can confidently say that we are still investing, caring and battling on behalf of the entire Duchenne community. As we push through this coronavirus crisis, and when it passes, our loved ones will still have CureDuchenne’s unwavering commitment to funding impactful research.
Developing a cure for a rare disease like Duchenne is complicated. It requires innovation, creativity, and perseverance. That perseverance means finding alternative approaches to the same challenge, and today’s investment from CureDuchenne Ventures exemplifies our strategy. Building on the current promise of Exon skipping to increase Dystrophin production, Dyne’s proprietary approach seeks to increase efficiency and availability to more individuals with Duchenne.
CureDuchenne is a proud champion for the Duchenne community. We won’t be deterred, delayed or desert our mission. We remain committed to a cure through partnerships with organizations like Dyne.